Hu Yun, Jin Dongmei, Zhou Yichan, Cheng Ye, Cao Hongyong, Ma Yong, Zhang Wenling
Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Department of General Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 2310442, China.
Transl Cancer Res. 2020 Apr;9(4):2748-2757. doi: 10.21037/tcr.2020.02.51.
THY1 (CD90) is a heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein, which has been implicated in several cancers. But, the specific mechanism and function of the THY1 gene remains unclear in gastric cancer (GC).
To investigate the function of THY1 in GC and illustrate the potential mechanism, TCGA and FIREBROWSE were used to detect the THY1expression. GEPIA2 and Kaplan-Meier Plotter showed significant correlation among THY1 mRNA level, TNM stage and survival probability of GC patients.
THY1 was up-regulated apparently in GC in contrast to normal tissues and linked to TNM stage. GC patients with higher THY1 expression displayed lower overall survival (OS), first progression (FP) and post-progression survival (PPS). In vitro experiments showed that knockdown of THY1 suppressed proliferation, migration while increased autophagy level in GC cells. Immune factors may interact with THY1mRNA in GC and THY1 was found significantly linked with Tregs.
Our findings indicate that higher THY1 level is link to poor prognosis of GC patients. THY1may as well be used as a marker molecule for evaluating the tumor microenvironment status of GC patients and a target for immunotherapy.
THY1(CD90)是一种高度N-糖基化、糖磷脂酰肌醇(GPI)锚定的细胞表面蛋白,与多种癌症有关。但是,THY1基因在胃癌(GC)中的具体机制和功能仍不清楚。
为了研究THY1在GC中的功能并阐明潜在机制,使用TCGA和FIREBROWSE检测THY1表达。GEPIA2和Kaplan-Meier Plotter显示THY1 mRNA水平、TNM分期与GC患者生存概率之间存在显著相关性。
与正常组织相比,THY1在GC中明显上调,并与TNM分期相关。THY1表达较高的GC患者总体生存期(OS)、首次进展期(FP)和进展后生存期(PPS)较低。体外实验表明,敲低THY1可抑制GC细胞增殖、迁移,同时提高自噬水平。免疫因子可能在GC中与THY1 mRNA相互作用,并且发现THY1与调节性T细胞(Tregs)显著相关。
我们的研究结果表明,较高的THY1水平与GC患者的不良预后相关。THY1也可作为评估GC患者肿瘤微环境状态的标志物分子和免疫治疗靶点。